Thomas Enzler

Medicine · University of Michigan

Established · publishing since 1988Rising activity

Cholangiocarcinoma and Gallbladder Cancer Studies Gallbladder and Bile Duct Disorders Pancreatic and Hepatic Oncology Research Drug Transport and Resistance Mechanisms Biliary and Gastrointestinal Fistulas

Publications

124

Citations

4,205

Est. group size

Recurring co-author estimate

Active years

Publishing since 1988

In context

Among 4,953 established Medicine PIs within our index

Citations: 4,205cohort median 2,544

Publications / year (recent): 15.6cohort median 4.8

Typically publishes in teams of ~9 · 22% small-team papers (≤3 authors) · across 9 venues

Publication cadence

Publications per year over the last 10 years — averaging 15.6/year recently

Collaborators per year

Distinct co-authors at University of Michigan each year — a rough indication of whether the group around this researcher has been growing or contracting. An estimate from co-authorship, not a roster: collaborators are not necessarily lab members, and recent years can be under-counted while indexing catches up.

Recent publications

Pancreatic cancer precursor lesions – Can immunotherapy prevent progression into pancreatic ductal adenocarcinoma?
Cancer Letters · 2025
2223P First-line (1L) AZD0171 + durvalumab (D) + chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): Phase II study results
Annals of Oncology · 2025
A phase 1b/2 study to evaluate the safety and efficacy of TTI-101 as monotherapy and in combination in advanced hepatocellular carcinoma.
Journal of Clinical Oncology · 2024
Supplementary Figures 1-8 from Cell-Selective Inhibition of NF-κB Signaling Improves Therapeutic Index in a Melanoma Chemotherapy Model
2023
Supplementary Figures 1-8 from Cell-Selective Inhibition of NF-κB Signaling Improves Therapeutic Index in a Melanoma Chemotherapy Model
2023
Data from Cell-Selective Inhibition of NF-κB Signaling Improves Therapeutic Index in a Melanoma Chemotherapy Model
2023
Data from Cell-Selective Inhibition of NF-κB Signaling Improves Therapeutic Index in a Melanoma Chemotherapy Model
2023
Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma
OncoImmunology · 2022
872 Neoadjuvant chemoradiotherapy enhances T cell infiltration in pancreatic ductal adenocarcinoma but high percentage of regulatory T cells associates with poor survival
2020
Combining chemotherapy with PD-1 blockade in NSCLC
Pharmacology & Therapeutics · 2018
The Role of Oncolytic Viruses in the Treatment of Melanoma
Current Oncology Reports · 2018
Anaplastic Large Cell Lymphoma, ALK Positive
2018
Correction to: The Role of Oncolytic Viruses in the Treatment of Melanoma
Current Oncology Reports · 2018
Impact of microsatellite instability status and sidedness of the primary tumor on immunophenotype of colorectal cancer.
Journal of Clinical Oncology · 2018
Quantitative multiplex immune fluorescence to reveal the impact of chemoradiation therapy on modulation of the immune micro-environment of pancreatic ductal adenocarcinoma.
Journal of Clinical Oncology · 2018

Publishes in

Journal of Clinical Oncology×10
Journal of the National Comprehensive Cancer Network×3
Current Oncology Reports×2
Clinical Cancer Research×2
Annals of Oncology×2

Similar researchers

By research-topic overlap

Arathi Mohan
Medicine · University of Michigan
Srinadh Choppara
Medicine · University of Michigan
Olamide Animasahun
Medicine · University of Michigan
G.A. Poultsides
Medicine · The Ohio State University
Negin Karisani
Medicine · Purdue University West Lafayette

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 25, 2026.

Claim or correct this profile